Journal
JOURNAL OF THORACIC DISEASE
Volume 11, Issue -, Pages S81-S88Publisher
AME PUBL CO
DOI: 10.21037/jtd.2019.01.46
Keywords
Biomarkers; epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); BRAF; RET; MET; tumor mutational burden
Categories
Ask authors/readers for more resources
There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available